203 related articles for article (PubMed ID: 30942181)
1. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment.
Krens SD; Lassche G; Jansman FGA; Desar IME; Lankheet NAG; Burger DM; van Herpen CML; van Erp NP
Lancet Oncol; 2019 Apr; 20(4):e200-e207. PubMed ID: 30942181
[TBL] [Abstract][Full Text] [Related]
2. Single-dose pharmacokinetic studies of abiraterone acetate in men with hepatic or renal impairment.
Marbury T; Lawitz E; Stonerock R; Gonzalez M; Jiao J; Breeding J; Haqq C; Verboven P; Stieltjes H; Yu M; Molina A; Acharya M; Chien C; Tran N
J Clin Pharmacol; 2014 Jul; 54(7):732-41. PubMed ID: 24374856
[TBL] [Abstract][Full Text] [Related]
3. [Anticancer drugs management in renal insufficiency patients].
Zimmer-Rapuch S; Lheureux S; Brocard F; Janus N; Launay-Vacher V; Ray-Coquard I
Bull Cancer; 2012 Mar; 99(3):323-31. PubMed ID: 22123599
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and safety of revefenacin in subjects with impaired renal or hepatic function.
Borin MT; Lo A; Barnes CN; Pendyala S; Bourdet DL
Int J Chron Obstruct Pulmon Dis; 2019; 14():2305-2318. PubMed ID: 31632000
[TBL] [Abstract][Full Text] [Related]
5. Optimization of cancer chemotherapy on the basis of pharmacokinetics and pharmacodynamics: from patients enrolled in clinical trials to those in the 'real world'.
Fujita K; Sasaki Y
Drug Metab Pharmacokinet; 2014; 29(1):20-8. PubMed ID: 24256625
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment.
Devriese LA; Witteveen PO; Marchetti S; Mergui-Roelvink M; Reyderman L; Wanders J; Jenner A; Edwards G; Beijnen JH; Voest EE; Schellens JH
Cancer Chemother Pharmacol; 2012 Dec; 70(6):823-32. PubMed ID: 23010853
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and safety of cetuximab in a patient with renal dysfunction.
Krens LL; Baas JM; Verboom MC; Paintaud G; Desvignes C; Guchelaar HJ; Gelderblom H
Cancer Chemother Pharmacol; 2014 Jun; 73(6):1303-6. PubMed ID: 24705976
[TBL] [Abstract][Full Text] [Related]
8. Influence of renal and hepatic impairment on the pharmacokinetic and pharmacodynamic properties and tolerability of fluticasone furoate and vilanterol in combination.
Allen A; Davis A; Hardes K; Tombs L; Kempsford R
Clin Ther; 2012 Dec; 34(12):2316-32. PubMed ID: 23200625
[TBL] [Abstract][Full Text] [Related]
9. Dose adjustment for tyrosine kinase inhibitors in non‑small cell lung cancer patients with hepatic or renal function impairment (Review).
Zhao D; Chen J; Long X; Wang J
Oncol Rep; 2021 Feb; 45(2):413-426. PubMed ID: 33416184
[TBL] [Abstract][Full Text] [Related]
10. Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function.
Kintzel PE; Dorr RT
Cancer Treat Rev; 1995 Jan; 21(1):33-64. PubMed ID: 7859226
[TBL] [Abstract][Full Text] [Related]
11. A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function.
Sharma S; Witteveen PO; Lolkema MP; Hess D; Gelderblom H; Hussain SA; Porro MG; Waldron E; Valera SZ; Mu S
Cancer Chemother Pharmacol; 2015 Jan; 75(1):87-95. PubMed ID: 25377157
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacokinetics and impaired organic functions].
Chatelut E
Bull Cancer; 2011 Nov; 98(11):1347-54. PubMed ID: 22024557
[TBL] [Abstract][Full Text] [Related]
13. Practical treatment guide for dose individualisation in cancer chemotherapy.
Canal P; Chatelut E; Guichard S
Drugs; 1998 Dec; 56(6):1019-38. PubMed ID: 9878990
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of dalbavancin in patients with renal or hepatic impairment.
Marbury T; Dowell JA; Seltzer E; Buckwalter M
J Clin Pharmacol; 2009 Apr; 49(4):465-76. PubMed ID: 19318696
[TBL] [Abstract][Full Text] [Related]
15. Decreased Disposition of Anticancer Drugs Predominantly Eliminated via the Liver in Patients with Renal Failure.
Fujita K; Matsumoto N; Ishida H; Kubota Y; Iwai S; Shibanuma M; Kato Y
Curr Drug Metab; 2019; 20(5):361-376. PubMed ID: 30947665
[TBL] [Abstract][Full Text] [Related]
16. The effect of renal and hepatic impairment on the pharmacokinetics of ospemifene, a tissue-selective estrogen agonist/antagonist.
Preston RA; Marbury TC; Wajima T; Graham S
Am J Ther; 2015; 22(3):171-81. PubMed ID: 24413373
[TBL] [Abstract][Full Text] [Related]
17. Posology adjustments of oral antineoplastic agents for special populations: patients with renal impairment, hepatic impairment and hematologic toxicities.
González J; Quiroga M; Escudero-Vilaplana V; Collado-Borrell R; Herranz-Alonso A; Sanjurjo Sáez M
Expert Opin Drug Saf; 2018 Jun; 17(6):553-572. PubMed ID: 29781751
[TBL] [Abstract][Full Text] [Related]
18. Strength of evidence for labeled dosing recommendations in renal impairment.
Gagne JJ; Khan NF; Raj TS; Patel LR; Choudhry NK
Clin Trials; 2017 Apr; 14(2):219-221. PubMed ID: 27780884
[TBL] [Abstract][Full Text] [Related]
19. Protein intake in renal and hepatic disease.
Ambühl PM
Int J Vitam Nutr Res; 2011 Mar; 81(2-3):162-72. PubMed ID: 22139567
[TBL] [Abstract][Full Text] [Related]
20. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment: an update.
Giraud EL; de Lijster B; Krens SD; Desar IME; Boerrigter E; van Erp NP
Lancet Oncol; 2023 Jun; 24(6):e229. PubMed ID: 37269847
[No Abstract] [Full Text] [Related]
[Next] [New Search]
